Cited by 2,561Schizophrenia research and treatmentMental Health and PsychiatryTreatment of Major Depression

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Leucht, Stefan, Cipriani, Andrea, Spineli, Loukia, Mavridis, Dimitris, Örey, Deniz, Richter, Franziska, Samara, Myrto, Barbui, Corrado, Engel, Rolf R, Geddes, John R, Kissling, Werner, Stapf, Marko Paul, Lässig, Bettina, Salanti, Georgia, Davis, John M·2013·The Lancet

DOI 10.1016/s0140-6736(13)60733-3

Open this paper in CoChat — free account

Abstract

Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.Findings We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.Funding None.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)60733-3

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Self-citation
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521

Show all 61 references

Research works printed but not linked: 1

Leucht, 2009, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia, Am J Psychiatry, 166, 152, 10.1176/appi.ajp.2008.08030368 · DOI

Sorted by citations

Items 801–900 of 1,006

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial
Hasan, A., Roeh, A., Leucht, S., Langguth, B., Hansbauer, M., Oviedo-Salcedo, T., Kirchner, S. K., Papazova, I., Löhrs, L., Wagner, E. M., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100537 · Cited by 23
Self-citation
Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum
Lago, S. G., Tomasik, J., van Rees, G. F., Rubey, M., González‐Vioque, E., Ramsey, J. M., Haenisch, F., Broek, J. A. C., Vázquez-Bourgón, J., Papiol, S., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.07.043 · Cited by 23
Switching antipsychotics to support the physical health of people with severe mental illness: a qualitative study of healthcare professionals’ perspectives
Nash, A., Kingstone, T., Farooq, S., Tunmore, J., & Chew-Graham, C. A. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042497 · Cited by 20
Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders
Hopkins, S. C., Wilkinson, S., Corriveau, T. J., Nishikawa, H., Nakamichi, K., Loebel, A. D., & Koblan, K. S. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2282 · Cited by 23
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression
Loebel, A. D., Koblan, K. S., Tsai, J., Deng, L., D, M. F. M., KENT, J. M., & Hopkins, S. C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.109 · Cited by 22
A Novel Aminotetralin-Type Serotonin (5-HT) 2C Receptor-Specific Agonist and 5-HT2A Competitive Antagonist/5-HT2B Inverse Agonist with Preclinical Efficacy for Psychoses
Canal, C. E., Morgan, D., Felsing, D. E., Kondabolu, K., Rowland, N. E., Robertson, K. L., Sakhuja, R., & Booth, R. G. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212373 · Cited by 24
Adjunctive Brexpiprazole: A Review in Major Depressive Disorder
McKeage, K. (2016) · CNS Drugs · doi:10.1007/s40263-016-0320-0 · Cited by 23
Síndrome metabólico y antipsicóticos atípicos. Posibilidad de predicción y control
Pato, C. M. F., Molina, V., & Valverde, J. I. F. (2016) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2016.09.003 · Cited by 23
Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria
Murray, R. M., Correll, C. U., Reynolds, G. P., & Taylor, D. M. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317693200 · Cited by 23
Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence
Kleeblatt, J., Betzler, F., Kilarski, L. L., Bschor, T., & Köhler, S. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.03.003 · Cited by 25
Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature
Teodorescu, A., Ifteni, P. I., Moga, M., Burtea, V., & Bîgiu, N. F. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1475-z · Cited by 23
Glucose homeostasis in major depression and schizophrenia: a comparison among drug-naïve first-episode patients
Steiner, J. H., Fernandes, B. S., Guest, P. C., Dobrowolny, H., Meyer-Lotz, G., Westphal, S., Borucki, K., Schiltz, K., Sarnyai, Z., & Bernstein, H. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0865-7 · Cited by 23
Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis
Balijepalli, C., Druyts, E., Zoratti, M. J., Wu, P., Kanji, S., Rabheru, K., Yan, K., & Thorlund, K. (2018) · Schizophrenia Research and Treatment · doi:10.1155/2018/1543034 · Cited by 23
Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Saikia, S., Bordoloi, M., & Sarmah, R. (2018) · Current Drug Targets · doi:10.2174/1389450120666181105152439 · Cited by 23
Cardiac Sigma Receptors – An Update
Stračina, T., & Nováková, M. (2018) · Physiological Research · doi:10.33549/physiolres.934052 · Cited by 23
Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice
Cieślik, P., Radulska, A., Pelikant‐Małecka, I., Płoska, A., Kalinowski, L., & Wierońska, J. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112781 · Cited by 23
Resting-state functional connectivity of the striatum predicts improvement in negative symptoms and general functioning in patients with first-episode psychosis: A 1-year naturalistic follow-up study
Oh, S., Kim, M., Kim, T., Lee, T. Y., & Kwon, J. S. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419885452 · Cited by 23
Ranking Antipsychotics for Efficacy and Safety in Schizophrenia
Correll, C. U., & Kane, J. M. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.3377 · Cited by 23
Brexpiprazole
Markovic, M., Gallipani, A., Patel, K. H., & Maroney, M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028016678262 · Cited by 22
Physical activity and metabolic disease among people with affective disorders: Prevention, management and implementation
Vancampfort, D., & Stubbs, B. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.07.042 · Cited by 24
Suicidal Ideation in People With Psychosis Not Taking Antipsychotic Medication: Do Negative Appraisals and Negative Metacognitive Beliefs Mediate the Effect of Symptoms?
Hutton, P., Rienzo, F. D., Turkington, D., Spencer, H. M., & Taylor, P. J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby153 · Cited by 22
Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes
Kneller, L. A., Abad‐Santos, F., & Hempel, G. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00793-x · Cited by 22
Identifying influential factors distinguishing recidivists among offender patients with a diagnosis of schizophrenia via machine learning algorithms
Kirchebner, J., Günther, M. P., & Lau, S. (2020) · Forensic Science International · doi:10.1016/j.forsciint.2020.110435 · Cited by 22
Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies
Cepaityte, D., Siafis, S., & Papazisis, G. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113168 · Cited by 22
Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma
Persico, M., Abbruzzese, C., Matteoni, S., Matarrese, P., Campana, A. M., Villani, V., Pace, A., & Paggi, M. G. (2022) · Cells · doi:10.3390/cells11020263 · Cited by 21
Brain-Targeted Intranasal Delivery of Zotepine Microemulsion: Pharmacokinetics and Pharmacodynamics
Pailla, S. R., Sampathi, S., Junnuthula, V., Maddukuri, S., Dodoala, S., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050978 · Cited by 22
Comparative Effectiveness of Antipsychotics in Preventing Readmission for First-Admission Schizophrenia Patients in National Cohorts From 2001 to 2017 in Taiwan
Lin, Y., Wu, C., Liu, C., Kuo, P., Chan, H., & Chen, W. J. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac046 · Cited by 22
Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
Segura, À. G., Martínez-Pinteño, A., Gassó, P., Rodríguez, N., Bioque, M., Cuesta, M. J., González‐Peñas, J., García‐Rizo, C., Lobo, A., González-Pinto, A. M., et al. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.05.021 · Cited by 22
Longitudinal Network Analysis Reveals Interactive Change of Schizophrenia Symptoms During Acute Antipsychotic Treatment
Sun, Y., Zhang, Y., Lu, Z., Yan, H., Guo, L., Liao, Y., Lu, T., Wang, L., Li, J., Li, W., et al. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac131 · Cited by 21
Reproducible gut microbial signatures in bipolar and schizophrenia spectrum disorders: A metagenome-wide study
Ioannou, M., Borkent, J., Andreu‐Sánchez, S., Wu, J., Fu, J., Sommer, I. E., & Haarman, B. C. M. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.07.009 · Cited by 23
Desvenlafaxine for the Acute Treatment of Depression: A Systematic Review and Meta-analysis
Laoutidis, Z. G., & Kioulos, K. T. (2015) · Pharmacopsychiatry · doi:10.1055/s-0035-1555879 · Cited by 22
Augmenting Selective Serotonin Reuptake Inhibitors With Clomipramine in Obsessive-Compulsive Disorder: Benefits and Risks
Andrade, C. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13f08883 · Cited by 22
Aerobic capacity is associated with global functioning in people with schizophrenia
Vancampfort, D., Guelinckx, H., Probst, M., Ward, P. B., Rosenbaum, S., Stubbs, B., & Binder, M. D. (2015) · Journal of Mental Health · doi:10.3109/09638237.2015.1036974 · Cited by 22
Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia
Javitt, D. C. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0010-9 · Cited by 23
Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials
Matsuda, Y., Kishi, T., & Iwata, N. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.09.002 · Cited by 22
Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K Pathway
Karbownik, M. S., Szemraj, J., Wieteska, Ł., Antczak, A. J., Górski, P., Kowalczyk, E., & Pietras, T. (2016) · Pharmacology · doi:10.1159/000444534 · Cited by 19
Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects
Chong, J. W. X., Tan, E. H.-J., Chong, C. E., Ng, Y., & Wijesinghe, R. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.07.178 · Cited by 22
Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1:Magnitude and Moderators of the Problem
Andrade, C. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16f10997 · Cited by 22
First and second generation antipsychotics differentially affect structural and functional properties of rat hippocampal neuron synapses
Gottschling, C., Geißler, M., Springer, G., Wolf, R. J., Juckel, G., & Faissner, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.08.055 · Cited by 22
Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future Applications
Berrouiguet, S., Barrigón, M. L., Brandt, S. A., Ovejero, S., Álvarez-García, R., Carballo, J. J., Lenca, P., Courtet, P., MEmind Study Group, & Baca‐García, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163796 · Cited by 22
Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis
Bartoli, F., Dell’Osso, B. M., Crocamo, C., Fiorillo, A., Ketter, T. A., Suppes, T. M., Clerici, M., & Carrà, G. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.12.021 · Cited by 22
Antipsychotic Drugs in Schizophrenia: Relative Effects in Patients With and Without Treatment Resistance
Andrade, C. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16f11328 · Cited by 22
Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?
Citrome, L. (2016) · CNS Spectrums · doi:10.1017/s1092852916000729 · Cited by 22
Clozapine-induced, dilated cardiomyopathy: a case report
Longhi, S., & Heres, S. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2679-5 · Cited by 22
The affinity of antipsychotic drugs to dopamine and serotonin 5-HT2 receptors determines their effects on prefrontal-striatal functional connectivity
Tollens, F., Gass, N., Becker, R., Schwarz, A. J., Risterucci, C., Künnecke, B., Lebhardt, P., Reinwald, J., Sack, M., Weber‐Fahr, W., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.05.016 · Cited by 27
Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first‐episode psychosis with low‐risk of self‐harm or aggression. Study protocol and baseline characteristics of participants
O'Donoghue, B. N., Francey, S. M., Nelson, B., Ratheesh, A., Allott, K., Graham, J. R., Baldwin, L., Álvarez‐Jiménez, M., Thompson, A. D., Fornito, A., et al. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12716 · Cited by 22
Severe parkinsonism under treatment with antipsychotic drugs
Druschky, K., Bleich, S., Grohmann, R., Engel, R. R., Toto, S., Neyazi, A., Däubl, B., & Stübner, S. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01060-7 · Cited by 22
Self-citation
Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia
Puranen, A., Koponen, M., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02830-2 · Cited by 22
Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials?
Krol, F. J., Hagin, M., Vieta, E., Harazi, R., Lotan, A., Strous, R. D., Lerer, B., & Popović, D. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.12.117 · Cited by 22
The Antipsychotic Agent Sertindole Exhibited Antiproliferative Activities by Inhibiting the STAT3 Signaling Pathway in Human Gastric Cancer Cells
Dai, C., Liu, P., Wang, X., Yin, Y., Jin, W., Shen, L., Chen, Y., Chen, Z., & Wang, Y. (2019) · Journal of Cancer · doi:10.7150/jca.34847 · Cited by 22
Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists
Fagiolini, A. M., Brugnoli, R., Sciascio, G. D., Filippis, S. D., & Maina, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1013029 · Cited by 22
The effect of brexpiprazole in adult outpatients with early-episode schizophrenia
MALLA, A. K., Ota, A., Nagamizu, K., Perry, P. P., Weiller, E., & Baker, R. A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000140 · Cited by 22
Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia
Lago, S. G., & Bahn, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00205 · Cited by 23
Subjective Versus Objective Weight Gain During Acute Treatment With Second-Generation Antipsychotics in Schizophrenia and Bipolar Disorder
Gao, K., Fang, F., Wang, Z., & Calabrese, J. R. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000596 · Cited by 21
The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis
Kopelli, E., Samara, M. T., Siargkas, A., Goulas, A., Papazisis, G., & Chourdakis, M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113246 · Cited by 21
Self-citation
Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs
Koreki, A., Mori, H., Nozaki, S., Koizumi, T., Suzuki, H., & Onaya, M. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001421 · Cited by 21
The short and long-term effects of aerobic, strength, or mixed exercise programs on schizophrenia symptomatology
Garcés, L. G., Sánchez‐López, M. I., Cano, S. L., Meliá, Y. C., Marqués-Azcona, D., Biviá-Roig, G., Lisón, J. F., & Peyró-Gregori, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-03761-3 · Cited by 26
Mechanistic/mammalian target of rapamycin and side effects of antipsychotics: insights into mechanisms and implications for therapy
Zhuo, C., Xu, Y. J., Hou, W., Chen, J., Li, Q., Liu, Z., Dou, G., Sun, Y., Li, R., Ma, X., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-021-01778-w · Cited by 21
Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial
Bjarke, J., Gjerde, H. N., Jørgensen, H. A., Kroken, R. A., Løberg, E., & Johnsen, E. (2022) · Acta Neuropsychiatrica · doi:10.1017/neu.2022.9 · Cited by 21
Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Tondt, J., & Bays, H. E. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100017 · Cited by 22
Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia
O’Connell, K. S., Koch, E. M., Lenk, H. Ç., Akkouh, I. A., Hindley, G., Jaholkowski, P. P., Smith, R. L., Holen, B., Shadrin, A. A., Frei, O., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115217 · Cited by 22
Lurasidone in the treatment of schizophrenia: a critical evaluation
Bruijnzeel, D. M., Yazdanpanah, M., Suryadevara, U., & Tandon, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1058780 · Cited by 21
An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine
Wu, C., Yuen, J. W. Y., Boyda, H. N., Procyshyn, R. M., Wang, C. K., Asiri, Y. I., Pang, C. C. Y., Honer, W. G., & Barr, A. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107116 · Cited by 21
Double-Blind, Placebo-Controlled Study of the Efficacy of Reboxetine and Citalopram as Adjuncts to Atypical Antipsychotics for Negative Symptoms of Schizophrenia
Usall, J., López‐Carrilero, R., Iniesta, R., Roca, M., Caballero, M. I. I., Rodríguez–Jiménez, R., Oliveira, C., Bernardo, M., Corripio, I., Duran‐Sindreu, S., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08551 · Cited by 21
Educational disparities in antipsychotic drug use among older people with and without dementia in S weden
Wastesson, J. W., Weitoft, G. R., & Johnell, K. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12378 · Cited by 22
The Impact of Antipsychotic Polytherapy Costs in the Public Health Care in Sao Paulo, Brazil
Razzouk, D., Kayo, M., Sousa, A., Gregório, G., Cogo‐Moreira, H., Cardoso, A. A., & Mari, J. D. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124791 · Cited by 21
Lack of tolerable treatment options for patients with schizophrenia
Citrome, L., Eramo, A., Clement, F., Duffy, R. A., Legacy, S. N., Offord, S. J., Krasa, H. B., Johnston, S., Guiraud-Diawara, A., Kamat, S., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91917 · Cited by 21
Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia
Kumar, P. S., Anish, P., & Velayudhan, R. (2016) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.192016 · Cited by 21
Brain volume change in first‐episode psychosis: an effect of antipsychotic medication independent of BMI change
Jørgensen, K. N., Nesvåg, R., Nerland, S., Mørch-Johnsen, L. E., Westlye, L. T., Lange, E. H., Haukvik, U. K., Hartberg, C. B., Melle, I. S., Andreassen, O. A., et al. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12677 · Cited by 22
Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Okuyama, Y., Oya, K., Matsunaga, S., Kishi, T., & Iwata, N. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s125367 · Cited by 21
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia
Pae, C., Wang, S., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., Masand, P. S., Serretti, A., & Emsley, R. A. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000177 · Cited by 21
Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study
Smith, R. L., Haslemo, T., Andreassen, O. A., Eliasson, E., Dahl, M., Spigset, O., & Molden, E. (2017) · CNS Drugs · doi:10.1007/s40263-017-0469-1 · Cited by 21
Subchronic olanzapine exposure leads to increased expression of myelination-related genes in rat fronto-medial cortex
Ersland, K. M., Skrede, S., Stansberg, C. T., & Steen, V. M. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0008-3 · Cited by 21
Prevalence and correlates of antipsychotic polypharmacy in Hong Kong
Lung, S. L. M., Lee, E. H. M., Chen, E. Y. H., Chan, K. W. S., Chang, W. C., & Hui, C. L. M. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.03.012 · Cited by 21
No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months
Schoemakers, R. J., van Kesteren, C., van Rosmalen, J., Eussen, M. L. J. M., Dieleman, H. G., & Beex-Oosterhuis, M. M. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0111 · Cited by 21
Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles.
Ziaei, M., Massoudifar, A., Rajabpour-Sanati, A., Pourbagher‐Shahri, A. M., & Abdolrazaghnejad, A. (2019) · PubMed Central · doi:10.22114/ajem.v0i0.117 · Cited by 20
Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling
Li, P., Wang, Y., Liu, X., Zhou, Z., Wang, J., Zhou, H., Zheng, L., & Yang, L. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0287-9 · Cited by 22
Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit
de Almeida, V., Levin, R. R., Peres, F. F., Suiama, M. A., Vendramini, A. M., Santos, C. M., Silva, N. D., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.015 · Cited by 21
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on bipolar depression
Wang, D., & Osser, D. N. (2019) · Bipolar Disorders · doi:10.1111/bdi.12860 · Cited by 21
Clozapine modulates retinoid homeostasis in human brain and normalizes serum retinoic acid deficit in patients with schizophrenia
Regen, F., Cosma, N. C., Otto, L. R., Clemens, V., Saksone, L., Gellrich, J., Üsekes, B., Ta, T. M. T., Hahn, E. W., Dettling, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0791-8 · Cited by 25
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Citrome, L., Graham, C. E., Simmons, A., Jiang, Y., Todtenkopf, M. S., Silverman, B. L., DiPetrillo, L., Cummings, H., Sun, L., & McDonnell, D. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s313840 · Cited by 21
The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abbas, K. S., Eltaras, M. M., El‐Shahat, N. A., Abdelazeem, B., Shaqfeh, M., & Brašić, J. R. (2022) · Medicina · doi:10.3390/medicina58020213 · Cited by 23
Yoga versus non-standard care for schizophrenia
Broderick, J. M., Crumlish, N., Waugh, A., & Vancampfort, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012052.pub2 · Cited by 23
Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults
Roh, D., Jang, K. W., & Kim, C.-H. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1075 · Cited by 20
“Unlike other antipsychotics, aripiprazole is associated with fewer adverse effects such as sedation, weight gain, cholesterol and prolactin increase [31].”
Background
Efficacy and feasibility of the Integrated Psychological Therapy for outpatients with schizophrenia in Greece: Final results of a RCT
Rakitzi, S., Georgila, P., Efthimiou, K., & Mueller, D. R. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.05.039 · Cited by 20
Yoga as part of a package of care versus non-standard care for schizophrenia
Broderick, J. M., & Vancampfort, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012807 · Cited by 20
Impact of Timing following Acute Myocardial Infarction on Efficacy and Safety of Bone Marrow Stem Cells Therapy: A Network Meta‐Analysis
Liu, B., Duan, C., Luo, C.-F., Ou, C., Wu, Z., Zhang, J., Ni, X., Chen, P., & Chen, M. (2015) · Stem Cells International · doi:10.1155/2016/1031794 · Cited by 20
Inverse association between urbanicity and treatment resistance in schizophrenia
Wimberley, T., Pedersen, C. B., MacCabe, J. H., Støvring, H., Astrup, A., Sørensen, H. J., Horsdal, H. T., Mortensen, P. B., & Gasse, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.03.021 · Cited by 20
Using Photovoice to explore patients' experiences with mental health medication: A pilot study
Werremeyer, A. B., Kelly, G. A., & Skoy, E. T. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.05.142 · Cited by 22
Effects of Amisulpride Adjunctive Therapy on Working Memory and Brain Metabolism in the Frontal Cortex of Patients with Schizophrenia: A Preliminary Positron Emission Tomography/Computerized Tomography Investigation
Park, J. H., Hong, J. S., Kim, S. M., Min, K. J., Chung, U., & Han, D. H. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.2.250 · Cited by 19
Unbound Fraction of Clozapine Significantly Decreases with Elevated Plasma Concentrations of the Inflammatory Acute-Phase Protein Alpha-1-Acid Glycoprotein
Man, W. H., Wilting, I., Heerdink, E. R., Hugenholtz, G. W. K., Bognàr, T., ten Berg, M. J., van Solinge, W. W., Egberts, T. C. G., & van Maarseveen, E. M. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00744-6 · Cited by 20
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 23
Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial
Xiao, J., Huang, J., Long, Y., Wang, X., Wang, Y., Yang, Y., Hei, G., Sun, M., Zhao, J., Li, L., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.611070 · Cited by 21
Identifying pathways to early‐onset metabolic dysfunction, insulin resistance and inflammation in young adult inpatients with emerging affective and major mood disorders
Tickell, A. M., Rohleder, C., Ho, N., McHugh, C. M., Jones, G. R. D., Song, Y. J. C., Hickie, I. B., & Scott, E. M. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13260 · Cited by 20
Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses
Umpierrez, L. S., Costa, P. A., Michelutti, E. A., Baracz, S. J., Sauer, M. K., Turner, A. J., Everett, N. A., Arnold, J. C., McGregor, I. S., & Cornish, J. L. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06119-3 · Cited by 20
Antipsychotic treatment in elderly patients on polypharmacy with schizophrenia
Štuhec, M. (2022) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000808 · Cited by 20
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Bighelli, I., Rodolico, A., Siafis, S., Samara, M. T., Hansen, W., Salomone, S., Aguglia, E., Cutrufelli, P., Bauer, I. O. B., Bäckers, L., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014383.pub2 · Cited by 21
Self-citation
Shared decision making with schizophrenic patients: a randomized controlled clinical trial with booster sessions (DECIDE Study)
Pérez‐Revuelta, J. I., González‐Sáiz, F., Paño, J. M. P., Mongil-Sanjuan, J. M., Rodríguez‐Gómez, C., Muñoz-Manchado, L. I., Mestre-Morales, J., Berrocoso, E., & Moreno, J. M. V. (2023) · Patient Education and Counseling · doi:10.1016/j.pec.2023.107656 · Cited by 21
Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis
Feber, L., Peter, N. L., Schneider‐Thoma, J., Siafis, S., Bighelli, I., Hansen, W., Baldez, D. P., Salanti, G., Keefe, R. S. E., Engel, R. R., et al. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02213-5 · Cited by 19
Self-citation
Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data
Oh, G. H., Yu, J., Choi, K., Joo, E.-J., & Jeong, S.-H. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.1.46 · Cited by 20

Authors: Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M.
Affiliations: TUM Klinikum (DE)
University of Verona (IT)
University of Ioannina (GR)
Ludwig-Maximilians-Universität München (DE)
Warneford Hospital (GB)
University of Illinois Chicago (US)
Corresponding author: Leucht, Stefan
ORCID: Leucht, Stefan
Cipriani, Andrea
Spineli, Loukia
Mavridis, Dimitris
Samara, Myrto
Barbui, Corrado
Engel, Rolf R
Geddes, John R
Salanti, Georgia
Davis, John M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2013-09
Volume: 382
Issue: 9896
Pages: 951-962
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)60733-3
OpenAlex: W2009832071
Cited by: 2,561
References: 61
Citations by year: 2026: 134 · 2025: 135 · 2024: 161 · 2023: 146 · 2022: 182 · 2021: 215 · 2020: 223 · 2019: 221 · 2018: 217 · 2017: 228 · 2016: 255 · 2015: 243 · 2014: 160 · 2013: 36
FWCI: 164.63
Type: journal article
Language: en
Open access: closed
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0611-10150)
H. Lundbeck A/S
Medical Research Council
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, drug efficacy comparison, tolerability, Bayesian framework, weight gain, extrapyramidal symptoms, QTc prolongation, sedation, clozapine, amisulpride, olanzapine, risperidone, paliperidone, zotepine
MeSH terms: Adult, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks